The Pulmonary Hypertension Research Group

from the Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec

The Group was created in 2011 at the Research center of the Québec Heart and Lung Institut (CRIUCPQ) - affiliated to Laval University School of Medicine. The Group is supported by the CIHR Canadian research Chair in translational research in pulmonary vascular diseases.

The Group is a collaboration between clinical investigators and fundamental researchers working together according to a Translational-Clinical Research program unique to Canada.

The Group's Mission

The mission of the Pulmonary Hypertension Research Group is to improve the quality of life of pulmonary hypertension patients by providing the best available patient care coupled with innovative research. Our group is presently the repository for ongoing basic science, translational, and clinical studies on pulmonary hypertension.

Specifically, our mission is to elucidate the  pathogenesis of pulmonary hypertension, identify the mechanisms of this disease and develop new therapeutic approaches to improve pulmonary hypertension patients' quality of life.

Current research projects and clinical trials in our center include:

  • The role of microRNA in the pathogenesis of pulmonary hypertension
  • The Role of DNA damage in the etiology of pulmonary hypertension
  • The metabolic basis of pulmonary hypertension
  • Exercise physiology in Pulmonary hypertension patients
  • Peripheral Angiogenesis defects in PAH
  • Mechanisms responsible for pulmonary hypertension secondary to idiopathic pulmonary fibrosis

Pulmonary Hypertension

Pulmonary hypertension is a complex vascular disease for which treatments are limited and mortality and morbidity remain very high. It is necessary to gain greater understanding of the mechanisms responsible for disease pathogenesis in these patients to provide more comprehensive treatment options.

Pulmonary arterial hypertension (PAH), defined as a mean pulmonary artery pressure of >25 mm Hg at rest, a PCWP or LVEDP <15, and PVR > 240 dyneŸs/cm-5 (3 Wood units), rarely occurs as a single, individual disease [idiopathic pulmonary arterial hypertension (IPAH)] but much more commonly in association with other diseases such as connective tissue diseases, HIV infection, portal hypertension and hemoglobinopathies. Little is known regarding the pathogenesis of these disorders. As many share similar histologies, it is possible that common pathophysiologic mechanisms link these disorders.

Our goal is to identify these mechanisms and to develop new therapeutic approaches to tackle PAH.

Clinical projects within the group focus on disease outcomes, treatment and prognosis. Basic science and translational research projects focus on the use of molecular resources and biomarkers to identify novel molecules for further investigation.

© 2012 Université Laval. Tous droits réservés